close
Add to watchlist
Orthovita Inc (VITA) Healthcare, Medical Equipment & Supplies
Orthovita, Inc., an orthobiologics and biosurgery company, develops and markets medical devices. The company's orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone; and the biosurgery platform provides products for controlling intra-operative bleeding/hemostasis. Its product portfolio comprises VITOSS bone graft substitute, an ultra-porous resorbable beta-tricalcium phosphate bone void filler used in helping the body guide the three-dimensional regeneration of the patient's own bone; IMBIBE needles, syringes, and disposable delivery instrumentation, which provides spine and orthopedic surgeons with a method for harvesting a patient's own bone marrow; VITAGEL surgical hemostat, a composite liquid hemostat that combines the biomaterials bovine thrombin and bovine collagen with the patient's autologous plasma, and applied in the spine, hip, and knee replacement surgeries; and VITASURE, a plant-based absorbable hemostat product that can be deployed throughout surgery. The company also offers various products, including CORTOSS Bone Augmentation Material, a self-setting glass ceramic polymeric composite for use in various surgical procedures to provide structural stability and reinforcement of the bones after surgery; and ALIQUOT Delivery System that facilitates delivery of materials to bony sites, including delivery of CORTOSS product directly to the surgical site. Orthovita sells its products in the United States and internationally through a network of direct sales representatives and independent non-stocking distributors. The company has strategic agreements with Kensey Nash Corporation; Angiotech Pharmaceuticals (U.S.), Inc.; and Medafor, Inc. Orthovita was founded in 1992 and is headquartered in Malvern, Pennsylvania.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 9999.99 |
| Volume | (mio) 1.9 |
| Volume Avg | (mio) 1081.59 |
| 52 Week High | 1.60 |
| 52 Week Low | -0.07 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | 0.00 |
| EPS change Q/Q | -60% |
| EPS change Q/Q Yr ago | 0% |
| EPS change Q/Q next Q est | 1000% |
| EPS change Y/Y | -37.5% |
| REV change Q/Q | 1.71% |
| REV change Q/Q Yr ago | -1.24% |
| EPS next Q est | 4.80 |
| EPS next Y est | -0.01 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |